Dyslipidaemia is a major risk factor for atherosclerotic coronary heart disease, which in turn is the commonest cause of mortality in type 2 diabetes. This highlights the importance of appropriate management of diabetic dyslipidaemia. Management is typically multifactorial and includes dietary recommendations, routine physical exercise, aggressive control of other lifestyle risk factors, and for many patients drug intervention. Future drug treatments will increasingly target not only mechanisms that might improve glucose and LDL cholesterol blood levels, but also improve other facets of diabetic dyslipidaemia, atherogenesis and vascular risk.
Ford ES, Giles WH, Dietz WHPrevalence of the metabolic syndrome among US adults. JAMA2002;287:356-9.
2.
Executive summary of the third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA2001;28:2486-97.
3.
Haffner SM, Lehto S., Ronnemaa T., Pyorala K., Laakso M.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med1998;339:229-34.
4.
Durrington P.Clinical trials of lipid-lowering medication in diabetes. Br J Diabetes Vasc Dis2003;3:217-20.
5.
Ginsberg HN, Illingworth DRPostprandial dyslipidaemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol2001; 88(6A):9H-15H.
6.
Gotto AMLipid management in diabetic patients: lessons from prevention trials . Am J Med2002;112(suppl 8A):19S-26S.
7.
Wilson PWF.Diabetes mellitus and coronary heart disease . Endocrinol Metab Clin2001;30:857-81.
8.
Superko HRLipoprotein subclasses and atherosclerosis. Front Biosc2001;6:D355-65.
9.
Buse JBLipid changes associated with diabetes therapy. Practical Diabetology2003;March:24-9.
10.
McPherson R.In people with no prior history of cardiovascular disease, high-density and non-high-density lipoprotein cholesterol levels are better predictors of cardiovascular disease mortality than low-density lipoprotein levels. Evid Based Cardiovasc Med2002;6(1):19-20.
11.
Austin MA, Edwards KLSmall, dense low-density lipoproteins, the insulin resistance syndrome and non-insulin-dependent diabetes. Curr Opin Lipidol1996;7:167-71.
12.
Bays HEExisting and investigational combination drug therapy for high-density lipoprotein cholesterol. Am J Cardiol2002 ;90(suppl):30K-43K.
Boden G.Pathogenesis of type 2 diabetes. Endocrinol Metab Clin2001; 30:801-15.
15.
Kashyap S., Belfort R., Pratipanawatr T.Chronic elevation in plasma free fatty acids impairs insulin secretion in non-diabetic offspring with a strong family history of type 2 diabetes mellitus . Diabetes2002;51(suppl 2):A12.
16.
Zhou YP, Grill V.Long-term exposure to fatty acids and ketones inhibits B-cell function in human pancreatic islets of Langerhans. J Clin Endocrinol Metab1995;80:1584-90.
17.
Kwiterovich POLipoprotein heterogeneity: diagnostic and therapeutic implications. Am J Cardiol2002 ;90(8A):1i-10i.
18.
Sacks FM, and the Expert Group on HDL Cholesterol.The role of highdensity lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol2002;90: 139-43.
19.
Goldberg GJInsulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol2001;90(suppl 5A):965-71.
20.
Diabetes Prevention Program Research Group.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002 ;346:393-403.
21.
Camejo G., Rosengren B., Hallberg C., Wallin B.PPAR agonists vascular effects contributing to their apparent anti-atherogenic action. Presented at the 2nd International Symposium on PPARs: from basic science to clinical applications. March, 2003.
22.
Lund EG, Menke JG, Sparrow CPLiver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Throm Vasc Biol2003;23:1169-77.
23.
Bays HE, Dujovne CAAnti-obesity drug development. Expert Opin Investig Drugs2002;11:1189-204.
